A randomised, multicentre study of first-line treatment of postmenopausal metastatic breast cancer, comparing concurrent vs sequential chemoendocrine therapy with Letrozole vs Letrozole single agent.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2016
At a glance
- Drugs Letrozole (Primary) ; Hormone modulators
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Dec 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network record.
- 26 Aug 2009 New trial record